Core Viewpoint - The article highlights the successful overseas application of domestic high-end clinical instruments by 聚光科技, particularly focusing on the deployment of their fully automated capillary electrophoresis instrument in Vietnam, which demonstrates the company's capability in providing localized solutions for complex clinical needs [5][19]. Group 1: Company Overview - 聚光科技 specializes in the independent research and development of high-end scientific instruments, focusing on industry-specific application needs and providing domestic, intelligent system solutions across key sectors such as ecological environment, industrial manufacturing, higher education research, and life sciences [2]. Group 2: Product Application and Performance - The fully automated capillary electrophoresis instrument from 聚拓生物 is operational in a comprehensive hospital in Hanoi, Vietnam, aiding local doctors in risk assessment for thalassemia [5]. - The instrument has been optimized to adapt to local sample characteristics, addressing the complexity of thalassemia in Vietnam, where genetic diversity and sample structure present unique challenges [7][8]. - The instrument's algorithm has been specifically optimized to enhance the recognition of HbE variant characteristics and key peak features, improving the stability and interpretability of electrophoresis results [8][10]. Group 3: Clinical Implementation and Feedback - The initial deployment faced challenges due to the complexity of local clinical samples, requiring careful calibration and parameter optimization to ensure reliable and repeatable readings [11][12]. - Continuous on-site analysis and remote collaboration were conducted to enhance the stability of peak recognition, leading to clearer and more stable peak shapes as reported by local clinical teams [13][16]. - The successful implementation and positive feedback from local medical staff reflect the technical strength of the instrument and the comprehensive service system provided by 聚拓生物 [17]. Group 4: Global Expansion and Future Outlook - The successful case in Vietnam serves as a strong practical example for 聚拓生物's overseas expansion, with recent project wins for the capillary electrophoresis instrument in Germany and Congo [19]. - The life sciences segment of 聚光科技 has also delivered multiple applications of its liquid chromatography-tandem mass spectrometry (LC-MS/MS) systems overseas, expanding the international application boundaries of domestic high-end scientific instruments [19]. - The company aims to continue promoting precise detection solutions tailored to the clinical needs of different countries and regions, facilitating the global reach of Chinese life science technology [23].

Core Viewpoint - Mindray has submitted its application for listing on the Hong Kong Stock Exchange, revealing that nearly 50% of its revenue comes from overseas, while also highlighting 11 global risks associated with its international operations [3][4]. Group 1: Listing Application and Revenue Breakdown - Mindray submitted its application for H-share listing on November 10, 2025, to the Hong Kong Stock Exchange [4]. - As of H1 2025, overseas revenue accounted for 49.8% of total revenue, with Europe contributing 9.4%, North America 7.9%, and Latin America 8.3% [5][6]. - The company has achieved a gross profit margin exceeding 60% in H1 2025, positioning it among the top global scientific instrument companies [7]. Group 2: Financial Performance - The total revenue for Mindray in 2022 was approximately RMB 30.37 billion, increasing to RMB 34.93 billion in 2023, and projected to reach RMB 36.73 billion in 2024 [8]. - The gross profit for the same periods was RMB 18.88 billion in 2022, RMB 22.42 billion in 2023, and is expected to be RMB 23.18 billion in 2024 [8]. - The net profit for H1 2025 is projected to be RMB 6.25 million, following a net profit of RMB 9.61 billion in 2022 and RMB 11.58 billion in 2023 [8]. Group 3: Global Risks - Mindray faces various risks in its global operations, including unfamiliarity with overseas regulations and compliance requirements [9]. - Political and economic changes in specific countries or regions, such as instability, inflation, and trade barriers, pose additional risks [9]. - The company also faces challenges related to product liability lawsuits and regulatory scrutiny in international markets [9]. Group 4: Implications for the Industry - The 11 identified risks are highly relevant and serve as significant warnings for other domestic instrument manufacturers looking to expand internationally [10].

Core Viewpoint - The "Domestic Instruments and Analytical Testing Innovation Development Forum" focuses on the innovation and development of domestic instruments, discussing technological breakthroughs, certification systems, and internationalization paths to promote an open and collaborative analytical testing ecosystem [2][3][5][44]. Group 1: Forum Overview - The forum was held on September 11, 2025, in Beijing, as part of BCEIA 2025, organized by the Instrument Information Network and supported by various associations [3][5]. - Representatives from government, industry associations, research platforms, universities, and domestic instrument companies participated in discussions on key topics such as technological breakthroughs and application ecosystems [5][6]. Group 2: Key Reports and Insights - A report highlighted that China's scientific instrument market exceeded 220 billion yuan in 2023, growing by 12% year-on-year, with a significant reliance on imports, particularly in large scientific instruments (70% imported) and analytical instruments (over 90% imported) [16][21]. - The Beijing government introduced the "High-end Scientific Instrument Innovation Development Action Plan (2025-2027)" aiming to break through 30 key components and develop over 50 complete products by 2027, fostering a competitive industrial ecosystem [17][18]. Group 3: Certification and Quality Assurance - A report discussed the necessity of establishing a quality certification system for domestic instruments, led by the China Certification and Accreditation Association, to address market trust issues and enhance product quality [26][27]. - The certification system will focus on local development and production of core components, ensuring comprehensive evaluation of product performance and quality management [27]. Group 4: Industry Challenges and Strategies - Domestic instrument companies face challenges such as increased competition and brand recognition issues, necessitating a dual strategy of internal management optimization and external market expansion [21]. - Companies are encouraged to leverage local industry clusters' advantages and focus on technology-driven growth to enhance global competitiveness [21]. Group 5: Application and Innovation - The "Good Domestic Instruments" project has evaluated over 400 domestic instruments, providing authoritative endorsements and user feedback to enhance brand recognition and application promotion [24]. - Reports emphasized the importance of integrating AI technology with analytical testing to improve the accuracy and efficiency of domestic instruments [28]. Group 6: Regional Development and Collaboration - Sichuan Province is actively promoting the application and innovation of domestic scientific instruments through collaborations with educational institutions and industry, aiming to enhance technical capabilities [34]. - The forum also recognized outstanding domestic instruments, showcasing the achievements of various companies in the industry [43].

Core Viewpoint - The article highlights the resilience and innovative vitality of China's scientific instrument industry in the face of global challenges, showcasing significant growth in overseas revenue among domestic listed companies [2][6]. Group 1: Overview of Overseas Revenue - In 2024, the total overseas revenue of 43 domestic listed instrument companies reached 34.707 billion yuan, marking a new high [6][10]. - Over 60% of the companies reported revenue growth, with 21 companies achieving over 100 million yuan in overseas revenue [6][10]. - The top five companies by overseas revenue are Mindray Medical (16.434 billion yuan), Sunny Optical (9.602 billion yuan), Libang Instruments (1.098 billion yuan), BGI Genomics (913 million yuan), and Huashengchang (717 million yuan) [3][6]. Group 2: Performance Analysis - Among the 43 companies, 27 experienced stable or significant growth, with notable examples including Wanyi Technology, which saw a 447.23% increase in overseas revenue [7][12]. - Conversely, 14 companies faced revenue declines, such as Gaode Infrared, which reported a 50.76% drop [7][15]. - Mindray Medical's overseas revenue accounted for 44.75% of its total revenue, reflecting the effectiveness of its globalization strategy [10][17]. Group 3: Market Dynamics - The article indicates a shift in the market, with three companies achieving over 1 billion yuan in overseas revenue, while 18 companies fall within the 100 million to 1 billion yuan range [13]. - Companies with overseas revenue constituting over 10% of total revenue increased to 22, indicating a growing trend in international market engagement [17]. - Wanyi Technology's strategy of "product leadership, quality excellence, competitive pricing, and superior service" has led to substantial growth in overseas markets [13][17]. Group 4: Emerging Companies - New entrants like Titan Technology and Lihua Technology reported 100% growth in overseas revenue, reflecting successful market expansion strategies [14]. - Titan Technology leveraged partnerships with overseas distributors and acquisitions to enhance its competitive brand presence [14]. Group 5: Future Outlook - Despite external uncertainties, the overall trend indicates a robust commitment from Chinese companies to expand in international markets, suggesting a "fast forward" approach to globalization [17].

导读： 在全球贸易保护主义升温、跨境供应链剧烈动荡的当下，中国科学仪器产业出海该往哪走？企业出海战略应如何调整？这场将 于上海松江召开的产业盛会将给出解答！ 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 中国发展离不开世界，世界发展也需要中国。 在国内市场"疯狂内卷"和全球产业链重组的大背景下，出海正在成为支撑中国科学仪器仪器发展的新增长引擎。 回顾过往，我们可以看到中国科学仪器企业不断加速"走出去"的步伐，东南亚、欧洲、非洲、墨西哥. . .到处都能听到 中国企业落地生长的故事，有不少人正在抵达的路上，更多的人还在打探、关注、调研。 国产仪器出海现状如何？有哪些机遇和挑战？在全球贸易保护主义升温、跨境供应链剧烈动荡的当下，出海的下一步又 该往哪走？ 科学仪器行业出海现状 当前，国产科学仪器行业正处于关键破局节点，在突破国内 "卡脖子" 重围的同时，也在积极寻求全球市场的商业机 遇，"出海" 成为众多企业发展战略中的重要一环。 仪器信息网数据显示， 从2019到2023年，中国科学仪器出口规模整体呈上升趋势，到2023年已达到42 ...